Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Hepatobiliary disorders – page 11

  • 357 clinical trials
  • 141 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Hepatocellular carcinoma89Cholangiocarcinoma38Hepatic cirrhosis25Metabolic dysfunction-associated steatohepatitis22Colorectal cancer20Non-alcoholic steatohepatitis17Chronic hepatitis B16Hepatitis D14Primary biliary cholangitis14Cholangitis sclerosing12Endometrial cancer12Non-small cell lung cancer12Alpha-1 antitrypsin deficiency11Gastric cancer11Malignant melanoma11Biliary neoplasm10Hepatitis B10Breast cancer9Ovarian cancer9Bile duct cancer8Gallbladder cancer8Hepatic cancer8Pancreatic carcinoma8Adenocarcinoma pancreas7+215

Clinical trials in Hepatobiliary disorders

357 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

357 clinical trials

Hepatotoxicity

Recruiting

Study on the Effectiveness and Safety of Prednisone for Patients with Drug-Induced Liver Injury (DILI)

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud

Crigler-Najjar syndrome

Recruiting

Study on Gene Therapy GNT0003 for Patients with Severe Crigler-Najjar Syndrome Requiring Phototherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Genethon

Cholangiocarcinoma

Recruiting

Study on the Effectiveness of Floxuridine with Gemcitabine and Oxaliplatin for Patients with Intra-hepatic Cholangiocarcinoma Not Suitable for Surgery

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Floxuridine
  • Sponsor:Oslo University Hospital HF

Cholangitis sclerosing

Recruiting

Study of Oral Vancomycin for Adults and Young Adults with Primary Sclerosing Cholangitis

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Vancomycin
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Biliary neoplasm

Recruiting

Study on Maintenance Therapy with Cisplatin, Durvalumab, and Trastuzumab for Patients with Advanced Biliary Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Unicancer

Hepatocellular carcinoma

Recruiting

Study on UCPVax, Atezolizumab, and Bevacizumab for Patients with Unresectable Liver Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:CHUR Of Besançon

Cholangiocarcinoma

Recruiting

Study on Hilar Cholangiocarcinoma Treatment Using Porfimer Sodium and Foscan for Patients with Bile Duct Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Universitaet Leipzig

Congenital absence of bile ducts

Recruiting

Study on Long-term Effects and Safety of Odevixibat in Children with Biliary Atresia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Hepatic cirrhosis

Recruiting

Study on Human Serum Albumin and Sodium Chloride for Patients with Liver Cirrhosis and Ascites

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Serum Albumin
  • Sponsor:European Foundation For The Study Of Chronic Liver Failure

Cholangiocarcinoma

Recruiting

Study on Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Servier Affaires Medicales

Alpha-1 antitrypsin deficiency

Recruiting

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Hepatitis D

Recruiting

Study on the Effects and Safety of Bulevirtide, Peginterferon Alfa-2a, and Entecavir in Patients with Chronic Hepatitis D

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Karolinska University Hospital

Substances studied in this area

The therapies tested most often in Hepatobiliary disorders trials.

Durvalumab37 clinical trialsBevacizumab29 clinical trialsAtezolizumab27 clinical trialsCisplatin26 clinical trialsLenvatinib22 clinical trialsTremelimumab22 clinical trialsGemcitabine20 clinical trialsInfliximab15 clinical trialsMycophenolate Mofetil15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.